Clinical Trials Logo
  1. Home
  2. Stage III Breast Cancer
  3. NCT01907529

A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer — TENDENCY  

Stage III Breast Cancer Clinical Trial

Official title:
A Trail of Neoadjuvant Endostar in Combination With Docetaxel, Epirubicin and Cyclophosphamide in Patients With Stage III Breast Cancer (TENDENCY)

Clinical Trial Summary

The trial was designed to study the efficacy and safety of neoadjuvant docetaxel, epirubicin in combination with cyclophosphamide(DEC) plus human recombinant endostatin (endostar) for breast cancer patients. The hypothesis of this protocol is that the combined an active angiogenesis agent to chemotherapy could enhance the pathological responce rate and further benefit breast cancer patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01907529
Study type Interventional
Source Hebei Medical University Fourth Hospital
Contact
Status Enrolling by invitation
Phase Phase 2/Phase 3
Start date August 2019
Completion date December 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03156309 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Terminated NCT00148720 - Capecitabine in Women With Operable Breast Cancer Phase 2
Active, not recruiting NCT02780401 - Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission Phase 1
Recruiting NCT06087120 - Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting NCT04553770 - Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer Phase 2
Completed NCT03364348 - 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Phase 1
Completed NCT00262834 - Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer Phase 2
Active, not recruiting NCT02445391 - Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Phase 3
Recruiting NCT04589468 - Researching the Effect of Exercise on Cancer N/A
Active, not recruiting NCT03044730 - Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Phase 2
Completed NCT00148681 - Preoperative Herceptin and Navelbine for Breast Cancer Phase 2
Terminated NCT02096588 - Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin Phase 2
Completed NCT03139435 - Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer N/A
Terminated NCT01194427 - A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer Phase 2
Recruiting NCT05535192 - TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients N/A
Recruiting NCT05595577 - Improving Exercise Capacity With a Tailored Physical Activity Intervention N/A
Active, not recruiting NCT03387553 - HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer Early Phase 1
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Active, not recruiting NCT02157051 - Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer Phase 1
Not yet recruiting NCT02115152 - Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer Phase 2